Article citationsMore>>

Hanna, N., Shepherd, F.A., Fossella, F.V., Pereira, J.R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T.C., Pless, M., Muller, T., Lim, H.L., Desch, C., Szondy, K., Gervais, R., Shaharyar, Manegold, C., Paul, S., Paoletti, P., Einhorn, L. and Bunn Jr., P.A. (2004) Randomized Phase III Trial of Pemetrexed versus Docetaxel in Patients with Non-Small-Cell Lung Cancer Previously Treated with Chemotherapy. Journal of Clinical Oncology, 22, 1589-1597.
http://dx.doi.org/10.1200/JCO.2004.08.163

has been cited by the following article:

• TITLE: Good Response to Pemetrexed after Treatment Failure with Another Thymidylate Synthase Inhibitor in Lung Adenocarcinoma: A Case Report

  AUTHORS: Fumihiko Hirai, Eiko Inamasu, Gouji Toyokawa, Tsukihisa Yoshida, Kaname Nosaki, Tomoyoshi Takenaka, Masafumi Yamaguchi, Mitsuhiro Takenoyama, Takashi Seto, Yukito Ichinose

  KEYWORDS: Pemetrexed, S-1, Thymidylate Synthase

  JOURNAL NAME: Journal of Cancer Therapy, Vol.5 No.8, July 10, 2014

  ABSTRACT: Pemetrexed is an antimetabolic agent and is well-known as a potent inhibitor of thymidylate synthase (TS). It also inhibits dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyl transferase (GARFT). We reported an intriguing case in which a non-small cell lung cancer patient who was refractory to pretreatment with S-1, a strong TS inhibitor, showed good response to pemetrexed treatment.